<DOC>
	<DOCNO>NCT01167881</DOCNO>
	<brief_summary>This pivotal phase III study , mandatory seek approval regulatory authority BI 10773 anti-diabetic agent compare active comparator patient type 2 diabetes mellitus insufficient glycaemic control .</brief_summary>
	<brief_title>Efficacy Safety Empagliflozin ( BI 10773 ) With Metformin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Diagnosis typ 2 diabetes mellitus Male female diet exercise regimen , pretreated metformin 12 week prior randomisation HbA1c equal great 7.0 % less equal 10 % visit 1 18 year BMI equal less 45Kg/m2 Exclusion criterion : Uncontrolled hyperglycemia define glucose 13.3 mmol/L overnight fast placebo runin Any antidiabetic drug within 12 week prior randomisation except metformin Acute coronary syndrome ( nonSTEMI , STEMI unstable angina pectoris ) , stroke transient ischemic attack within 12 week inform consent Indication liver disease Moderate severe renal impairment Bariatric surgery within past 2 year Medical history cancer treatment cancer within last 5 year Blood dyscrasia disorder cause haemolysis unstable red blood cell Contraindications hypersensitivity concomitant drug Treatment antiobesity drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>